BIL010t (formerly known as BSCT), a non-functional form of the P2X7 receptor (nf-P2X7) antibody used as topical therapy for basal cell carcinoma [11], and PBF-509, a potent A2A receptor antagonist for the treatment of non-small cell lung cancer [60], were both well-tolerated and safe in Phase I/II trials [11] (Table 3). This evidence concerns the gene P2RX7 and basal cell carcinoma.